No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
William Blair Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating
Xenon Pharmaceuticals Analyst Ratings
Goldman Sachs Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $52
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
William Blair Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
Xenon to Present at Stifel 2025 Virtual CNS Forum